Research Areas



  • Assay Type Sandwich ELISA
  • Sample Types Serum and EDTA Plasma
  • Sensitivity 0.31 pg/mL
  • Species Human
  • Assay Duration 2.5 Hours
  • Samples/Plate 40 in Duplicate
  • Readout Colorimetric, 450 nm
  • Standard Curve Human B-Type Natriuretic Peptide (BNP) ELISA kit
  • Description

    Assay Principle: 

    The Human B-Type Natriuretic Peptide (BNP) ELISA Kit quantitatively measures BNP in serum and EDTA plasma. The Human B-Type Natriuretic Peptide (BNP) ELISA Kit is a sandwich ELISA with a run time of 2.5 hours. Please read the complete kit insert for more information before performing this assay.

    Use our provided BNP standard to generate a standard curve for the assay. Pipette the standards or diluted samples into a transparent microtiter plate coated with our sheep anti-human B-Type Natriuretic Peptide antibody. Add the peroxidase-conjugated BNP monoclonal antibody. Then incubate the mixture covered at room temperature shaking for 2 hours. The immunological reaction occurs between the peroxidase-conjugated BNP monoclonal antibody and the BNP antigen in the sample or standard. 

    After the 2-hour incubation, wash away the excess peroxidase-conjugated BNP monoclonal antibody and add the TMB substrate. The TMB substrate reacts with the bound peroxidase-conjugated BNP monoclonal antibody generating a signal detected by a plate reader at 450nm. Use the intensity and the standard curve to calculate the BNP concentration in the samples.


    B-Type Natriuretic Peptide (BNP [formerly known as brain natriuretic peptide]) is an important hormone that regulates blood pressure and volume. In patients with heart failure, increased heart stretch or hypoxia can trigger BNP synthesis and secretion from ventricular cardiomyocytes, as opposed to its standard constitutive release from only the atrium. Upon secretion, proBNP is cleaved into active BNP (32 amino acids), having a half-life of 20 minutes, and inactive NT-proBNP (76 amino acids), having a half-life of 90 minutes. Patients suffering from heart failure and cardiac dysfunction have significantly elevated BNP serum levels, so this biomarker is an excellent addition to the diagnostic criteria for these diseases. Patients with serum concentrations greater than 100 pg/mL of BNP are likely to suffer from heart failure or cardiac dysfunction. Not only can you determine the diagnostic outcome from this biomarker, but you can also monitor treatment efficacy for patients suffering from heart failure or cardiac dysfunction